


supplementation with this extract increased survival as well as the tendency to reduce the expression of TGFβ1 induced by chemical damage.

**Conflict of interest:** None



<https://doi.org/10.1016/j.aohep.2025.102061>

#146

**INCIDENCE AND PREDICTORS OF POST-TRANSPLANT MALIGNANCY IN LIVER TRANSPLANT RECIPIENTS: A SINGLE-CENTRE COHORT STUDY**

Francisco Idalsoaga F.<sup>1</sup>, Pedro Acuña V.<sup>2</sup>,  
Abed Saqah<sup>3</sup>, Hashaal Alkhurassi<sup>3</sup>,  
Saad Moteb Aldosari<sup>3</sup>, Abdelrahman Sallam<sup>3</sup>,  
Rayad Elzaanoun<sup>3</sup>, Siddhant Maini<sup>3</sup>,  
Gopika Punchhi<sup>3</sup>, Rokhsana Mortuza<sup>3</sup>,  
Luis Antonio Diaz<sup>4</sup>, Mohammed Qasim K.<sup>3</sup>,  
Juan Pablo Arab<sup>5</sup>

<sup>1</sup> Universidad Católica de Chile / Western University. Canada.

<sup>2</sup> Universidad Católica de Chile.

<sup>3</sup> Western University. Canada.

<sup>4</sup> Universidad Católica de Chile / University of California San Diego. California. USA.

<sup>5</sup> Universidad Católica de Chile / Virginia Commonwealth University School of Medicine. Richmond. VA. USA.

**Introduction and Objectives:** Cancer is a major long-term complication after liver transplantation (LT). We aimed to characterize its incidence and risk factors in LT recipients at a Canadian center.

**Materials and Methods:** Retrospective cohort of patients who underwent LT from 2007–2018, with at least 60 months of follow-up. Demographic, clinical, and oncologic data were analyzed using Cox regression.


**Results:** We included 575 LT recipients (30% women, median age 53.6 years). Main etiologies were ALD (22.9%), HCV (20.8%), MASLD (13.3%), and PSC (11.1%). HCC was present at LT in 25.7%. During follow-up, 55 patients (9.7%) developed cancer, most commonly non-melanoma skin cancer (3.5% of all recipients), followed by head and neck tumors (1.0%), PTLN (0.9%), gastrointestinal cancers (0.9%), and neuroendocrine tumors (0.7%). Mean time to cancer diagnosis was 27.3±19.1 months. Additionally, 20 patients (3.4%) developed post-LT HCC, with 90% being recurrences. Cancer types differed by underlying etiology (p=0.004): non-melanoma skin cancers predominated in SLD and viral hepatitis, while GI cancers were most common in autoimmune liver disease. Among those with prior HCC, 16.8% developed a non-HCC cancer, mostly skin cancer. In multivariate analysis,

pre-LT HCC was independently associated with post-LT non-HCC cancer (HR 2.66; 95% CI 1.39–5.07; p=0.003), while age, gender, alcohol or tobacco use, and liver disease etiology were not.

**Conclusions:** Cancer occurred in nearly 10% of LT recipients, mostly within three years. A history of HCC at LT tripled the risk of subsequent non-HCC cancer, highlighting the importance of targeted cancer surveillance in this high-risk population.

**Conflict of interest:** None

**Distribution of cancer types by pre-transplant liver disease etiology**



<https://doi.org/10.1016/j.aohep.2025.102062>

#147

**THERAPEUTIC PLASMA EXCHANGE-INDUCED SHIFTS IN BILE SALT COMPOSITION IN ALCOHOL-ASSOCIATED HEPATITIS: INSIGHTS INTO MECHANISMS AND THERAPEUTIC POTENTIAL**

Francisco Idalsoaga F.<sup>1</sup>, Pedro Acuña V.<sup>2</sup>,  
Paula Rivera<sup>2</sup>, Luis Antonio Díaz Piga<sup>3</sup>, Fidel Allende<sup>4</sup>,  
Sandra Solari<sup>4</sup>, Nancy Solis<sup>5</sup>, Daniel Havaj<sup>6</sup>,  
Karolina Sulejova Sulejova<sup>6</sup>, Daniela Žilinanová<sup>5,6</sup>,  
Svetlana Selanová<sup>6</sup>, Libor Vitek<sup>7</sup>, Anand Kulkarni<sup>8</sup>,  
Juan Pablo Arab<sup>9</sup>, Lubomir Skladany<sup>10</sup>

<sup>1</sup> Departamento de Gastroenterología. Escuela de Medicina. Pontificia Universidad Católica de Chile. Division of Gastroenterology and Hepatology. Western University & London Health Sciences Centre, Canada.

<sup>2</sup> Departamento de Gastroenterología. Escuela de Medicina. Pontificia Universidad Católica de Chile.

<sup>3</sup> Departamento de Gastroenterología. Escuela de Medicina. Pontificia Universidad Católica de Chile. MASLD Research Center. Division of Gastroenterology and Hepatology. University of California San Diego, USA.

<sup>4</sup> Department of Clinical Laboratories. School of Medicine. Pontificia Universidad Católica de Chile.

<sup>5</sup> Departamento de Gastroenterología. Escuela de Medicina. Pontificia Universidad Católica de Chile. Santiago. Chile.

<sup>6</sup> Division of Hepatology. Gastroenterology and Liver Transplantation. Department of Internal Medicine II. Slovak Medical University. F. D. Roosevelt University Hospital, Slovak Republic.